To include your compound in the COVID-19 Resource Center, submit it here.

RPC1063: Additional Phase II data

Additional data from 258 patients with relapsing MS in the Phase II portion of the double-blind, international Phase II/III RADIANCE trial showed that once-daily 0.5 and 1 mg doses of oral RPC1063 each reduced the cumulative number of total gadolinium-enhancing lesions as

Read the full 429 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers